Characterisation of DWI-MRI confirmed cerebral infarcts in patients with subarachnoid haemorrhage and their association with MMP-9 levels

Fecha de publicación: 01/08/2015

Autores de IIS La Fe

Aida Lago Martín

Autor
José Ignacio Tembl Ferrairo

Autor
Rogelio Alberto Lopez Cuevas

Autor
Juana Valles Giner

Autor
Maria Teresa Santos Diaz

Autor
Antonio Moscardó Martínez

Autor
Vera Parkhutik Matveeva

Autor

Grupos

Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Investigador Principal

Pilar Medina Badenes

Abstract

Objectives: It has been suggested that metalloproteinase-9 (MMP-9) could predict the onset of cerebral vasospasm after subarachnoidal haemorrhage (SAH). The aim of this study was to analyse, in patients with SAH, the difference between patients with MRI ischaemic infarcts and patients without, and to investigate the role of metalloproteases as a prognostic factor for ischaemic infarcts. Methods: Sixty eight consecutive patients with SAH and diffusion-weighted magnetic resonance imaging (DWI-MRI) done 3 weeks after SAH. We define two groups, with and without DWI-MRI infarcts. Blood samples were taken at entry, 3 days and 1 week MMP-9 was determined through ELISA method. Results: Forty per cent were male, with a mean age of 54 +/- 14 years. Twenty five patients, 36.8%, had DWI-MRI infarcts; in patients with MRI infarcts, SAH was more severe (Fisher=4 52 vs 25.6%, P=0.037), with more morbi-mortality (Rankin>3 48 vs 18.6%, P=0.014), and more symptomatic vasospasm (28 vs 7%, P=0.031). Levels of MMP-9 were higher than controls, but there were no significant differences between patients with and without infarcts (first determination no infarcts 39.40 ng/ml +/- 35.40 vs infarcts 49.75 ng/ml +/- 34.54, P>0.005, 3 days no infarcts 72.10 ng/ml +/- 70.95 vs infarcts 62.28 +/- 33.84, P>0.005, 1 week no infarcts 148.48 ng/ml +/- 142.73 vs infarcts 91.51 ng/ml +/- 41.20, P>0.005). Conclusion: Thirty eight percent in a well-studied series of patients with SAH have DWI-MRI infarcts; the infarcts were associated to SAH severity, SAH outcome and symptomatic vasospasm. Metalloproteinase-9 was higher in SAH patients than in controls, but it could not discriminate the infarct patients.

Datos de la publicación

ISSN/ISSNe:: 0161-6412, 1743-1328
Tipo:: Article
Páginas:: 688-692
DOI:: 10.1179/1743132815Y.0000000045
Factor de Impacto:: 0,793 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

SAH; Matrix metalloproteinase; Vasospasm; Infarct; MRI

Campos de estudio

Proyectos asociados

INVESTIGACION EN RED DE LAS ENFERMEDADES NEUROLOGICAS

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

C03/06 . INSTITUTO DE SALUD CARLOS III . 2003

AVANCES EN EL ESTUDIO DE LA REACTIVIDAD PLAQUETARIA Y SU INTERACCION CON LOS ERITROCITOS: BASES MOLECUALRES Y APLICABILIDAD CLINICO-FARMACOLOGICA

Investigador Principal: JUANA VALLES GINER

PI03/0270 . INSTITUTO DE SALUD CARLOS III . 2004

RED DE INVESTIGACION (RENEVAS)

Investigador Principal: ENRIQUE ALBORCH DOMÍNGUEZ

RD06/0026/0006 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006